This is a preview of subscription content, log in via an institution to check access.
Reference
Haukaas FS, et al. Cost-Effectiveness of Obinutuzumab in Combination with Bendamustine Followed by Obinutuzumab Maintenance versus Bendamustine Alone in Treatment of Patients with Rituximab-Refractory Follicular Lymphoma in Norway. Applied Health Economics and Health Policy : 19 Jun 2018. Available from: URL: http://doi.org/10.1007/s40258-018-0401-y
Rights and permissions
About this article
Cite this article
Obinutuzumab cost effective for follicular lymphoma?. PharmacoEcon Outcomes News 806, 19 (2018). https://doi.org/10.1007/s40274-018-5062-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-018-5062-4